Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 9/20 | 0.36 |
| ▸ | RGS8 | P57771 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22898911 | 0.91 | HTT (0.34) | RGS4PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL22899086 | 0.89 | RGS4 (0.43) | RGS4PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL22899022 | 0.89 | RGS4 (0.43) | RGS4PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL19116664 | 0.87 | HTT (0.39) | ADORA2BL3MBTL1HTT | |
| SCHEMBL24404215 | 0.84 | RGS4 (0.41) | RGS4PDE4AADORA2AADORA2BPDE4B | |
| SCHEMBL22899028 | 0.84 | GRM2 (0.37) | HTT | |
| SCHEMBL11182513 | 0.80 | HTT (0.41) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL22898910 | 0.78 | HTT (0.40) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL22899034 | 0.78 | HTT (0.40) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL11185773 | 0.78 | HTT (0.40) | PDE4AADORA2AADORA2BPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | SLC9B2, SLC9A1, SLC9A2 | RGS4 2541/4885PDE4A 3232/4885ADORA2A 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.